Ever wondered why seasoned investors keep their eyes on small-cap biotech? It’s not just about the science—it’s about the massive potential of catching a company before it hits the big leagues. By targeting businesses under a $20 billion market cap, investors gain a unique advantage, especially through stock options that allow them to own a tangible piece of the future. Just look at the recent surge with Iovance Biotherapeutics; it’s a masterclass in how timing and strategic positioning can pay off when a stock takes flight. This is the playbook for spotting explosive growth before the rest of the market catches on. #BiotechInvesting #StockMarketTips #Investing101 #SmallCapStocks #WealthBuilding - @dansfera